Consolidation and maintenance therapy for transplant eligible myeloma patients
|
|
- Dayna Boyd
- 5 years ago
- Views:
Transcription
1 Consolidation and maintenance therapy for transplant eligible myeloma patients Teeraya Puavilai, M.D. Division of Hematology, Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University
2 Outlines Consolidation Maintenance Minimal residual disease
3 Definition and aim of consolidation and Consolidation therapy Short period: 2-4 cycles maintenance therapy Single agent or combination therapy or 2 nd ASCT Aim to increase the depth of response Maintenance therapy Longer period: 2-3 years or until disease progression Less intensive Aim to suppress any MRD with clinical objectives of prolonging response duration, PFS, and OS while minimizing toxicity
4 Consolidation therapy
5 What is the impact of consolidation therapy after ASCT? Post ASCT novel agent based consolidation therapy 2-4 cycles after ASCT To intensify therapy and improve depth of response 1 Spencer A et al. Lancet Haematology 2014;1(3):112-9
6 Post ASCT novel agent based consolidation therapy Reference Type of trial Treatment No. of patients Response rate EFS or PFS OS Bortezomib-based Cavo M et al 1 Phase III VTD vs TD 160 vs 161 CR/nCR pre consolidation: 63% vs 55% (P=NS) CR/nCR post consolidation: 73% vs 61% (P=0.02) Mellqvist UH et al 2 Phase III Bortezomib vs no consolidation Leleu X et al 3 Retrospective VTd vs no consolidation Ladetto M et al 4 Phase II VTD comsolidation 187 vs 183 VGPR pre consolidation: 40% vs 39% (P=NS) VGPR post consolidation: 71% vs 57% (P=0.009) 121 vs 96 CR post consolidation: 52% vs 30% (P=0.001) 39 CR pre VTD: 15% CR post VTD: 49% Tacchetti P et al 5 Phase III VTD vs TD 117 vs 117 CR/nCR post consolidation: 73% vs 61% P=0.012 Straka C et al 6 Phase III Bortezomib vs no consolidation 1 Cavo M et al. Blood 2012;120(1): Mellqvist UH et al. Blood 2013;121(23): Leleu X et al. Leukemia 2013;27(11): vs 185 VGPR pre consolidation: 55% vs 59% VGPR post consolidation: 62% vs 48% Median PFS for pts with <VGPR: 33% vs 25% P=0.009 Median PFS for high risk cytogenetic: 31% vs 24% P= yr PFS: 60% vs 48% P=0.042 Median PFS: 27 m vs 20 m P=0.05 Median TTP: NR vs 25 m P=0.005 Median PFS: 60 m Median PFS: 65 m vs 57 m P=0.001 Median PFS: 34 m vs 28 m P= yr OS: 90% vs 88% P=NS 3-yr OS: 80% vs 80% P=NS 4-yr OS: 84% vs 91% P=NS 3-yr OS: 89% 5-yr OS: 80% vs 73% P=NS Median OS: NR vs NR 4 Ladetto M et al. J Clin Oncol 2010;28(12): Tcchetti P et al. GMMY 3006 study ASH Ann Meet Abstr. 2014;124(21):196 6 Straka C et al. J Clin Oncol 2015;33(suppl):Abstrc 8511
7 Post ASCT novel agent based consolidation therapy Reference Type of trial Treatment No. of patients Response rate EFS or PFS OS Lenalidomide-based Attal et al 1 Phase III Len consolidation + len maintenance vs Len consolidation + placebo 307 vs 307 CR pre consolidation: 58% CR post consolidation: 69%% (P<0.001) Roussel et al 2 Phase II RVD consolidation 31 scr/cr pre VRD: 47% scr/cr post VRD: 50% NR after consolidation NR after consolidation 3-yr PFS: 77% 3-yr OS: 100% Ongoing trials IFM-Dana-Farber group Arm A: RVD 8 cycles then len maintenance 1 year Arm B: RVD 3 cycles then ASCT with melphalan 200 mg/m2 then RVD consolidation 2 cycles and len maintenance 1 year 3-yr PFS: 48% vs 61% P< CR rate: 46% vs 58% P<0.01 Median OS at 3 year: similar US trial using similar design but with len until progression 1 Attal et al N Engl J Med 2012;336: Roussel et al IFM 2008 ASH Ann Meet Abstrc 2011;118(21):1872
8 Summary of studies examining impact of cytogenetics on outcomes after ASCT N. Shah et al. Biol Blood Marrow Transplant 21 (2015)
9 Progression free survival from the landmark of starting consolidation therapy according to the presence or absence of cytogenetic abnormalities No cytogenetic abnormality or with del(13q) positivity but lack of t(4;14) and del(17p) t(4;14) and/or del(17p) positivity Mansour ZA and Ramanathan M. Advances in Hematology 2014
10 Maintenance therapy
11 What is the impact of maintenance therapy after ASCT? To achieve long term disease control To reduce risk of progression or relapse and to prolong OS Consist of a gentle treatment for a prolonged period with long term safety Several concerns: long term safety, financial burden, selection of treatment resistant clones, and consistent overall survival benefit remain Nathwami N et al. Curr Hematol Malig Res 2016;11:127-36
12 Thalidomide trials in the post ASCT PFS setting OS Patients with adverse cytogenetics [t(4;14),t(14;16),t(14;20),del17p,del1p32,gain 1q21]attained a similar PFS(9 v 12 months, P =.49) but a worse OS(P=.009). Mansour ZA and Ramanathan M. Advances in Hematology 2014
13 Meta analysis and systematic review showed collective data from thalidomide trials favoring maintenance Mansour ZA and Ramanathan M. Advances in Hematology 2014
14 Thalidomide maintenance A recent meta-analysis including 6 post-transplantation thalidomide studies confirmed similar findings of the clear PFS benefit of thalidomide maintenance (HR=0.67; p<0.001) but did not translate into an OS benefit (HR=0.90; p=0.343) The side effects of thalidomide limited long-term use, with the median duration of thalidomide maintenance varying from 7 24 months.(venous thrombosis and peripheral neuropathy) Wang Y et al J Natl Cancer Inst 2016 Mar;108(3)
15 Systematic review and meta-analysis Lenalidomide maintenance
16 Demographic & disease related characteristics at diagnosis: intention to treat population J Clin Oncol 35:
17 Demographic & disease related characteristics at diagnosis: intention to treat population J Clin Oncol 35:
18 Duration of maintenance therapy (safety population) Safety population includes patients who received at least one dose of study drug. J Clin Oncol 35:
19 Progression-free survival (PFS) analysis (intent-to-treat population) J Clin Oncol 35:
20 Hazard ratio for PFS by subgroup J Clin Oncol 35:
21 Overall survival J Clin Oncol 35:
22 Overall survival Hazard ratios (HRs) for OS by subgroup HRs for OS by prior induction subgroup J Clin Oncol 35:
23 Cumulative incidence curve of time to hematologic second primary malignancy (SPM) and solid tumor SPM onset (as-treated population) J Clin Oncol 35:
24 Cumulative incidence curves of time to disease progression and time to invasive SPM onset before disease progression J Clin Oncol 35:
25 Kaplan-Meier (KM) curve of time to death by cause of death J Clin Oncol 35:
26 Bortezomib maintenance trials In high-risk patients presenting with creatinine > 2 mg/dl and/or poor risk cytogenetic (deletion 17p13, t(4;14), and amplification of 1q21) bortezomib significantly improved both PFS and OS. Study Median FU Number Treatment Outcome HOVON 65 MM/ GMMG-HD4 41 months PAD/HDM/BORT q 2 wk for 2 yrs vs VAD/HDM/THAL 50 mg daily for 2 yrs PFS 35 months 28 months P < OS Median not reached HR = 0.77( ) P = PETHEMA/GEM 34.9 months VT THAL Interferon-α2b Significant PFS benefit for VT P < OS not significantly different between arms Induction regimen with VTD, TD or VBMCP/VBAD + V then ASCT Mohty M and Harousseau JL. Haematologica 2014;99(3):408-16
27 Bortezomib-based vs non-bortezomib-based post transplantation treatment in multiple myeloma patients: systematic review and meta-analysis of phase III RCT Flow diagram of study selection Liu et al. Onco Targets and Therapy 2015;8:
28 Patient demographics and baseline disease characteristics Liu et al. Onco Targets and Therapy 2015;8:
29 Bortezomib-based therapy of the included studies Systematic review and meta-analysis of phase III RCT Liu et al. Onco Targets and Therapy 2015;8:
30 Traditional and cumulative meta-analysis of response rates with bortezomib-based post-transplantation therapy ORR rate with bortezomib-based post-transplantation therapy CR/nCR rate with bortezomib-based post-transplantation therapy Liu et al. Onco Targets and Therapy 2015;8:
31 Traditional and cumulative meta-analysis of the outcomes Progression Free Survival (PFS) Overall Survival (OS) PFS: 27% reduction in risk of disease progression or death With bortezomib based therapy after ASCT OS: No statistical difference Liu et al. Onco Targets and Therapy 2015;8:
32 Traditional and cumulative meta-analysis of the frequency of grade 3 or 4 peripheral neuropathy Liu et al. Onco Targets and Therapy 2015;8:
33 Phase 3 trials evaluating novel agent-based maintenance therapy after ASCT Study Regimen Comparator Increased PFS? Increased OS? Lenalidomide Attal et al McCarthy et al Palumbo et al Thalidomide Attal et al Barlogie et al Spencer et al Lokhorst et al Morgan et al Stewart et al Bortezomib Sonneveld et al Rosinol et al LEN LEN LEN THAL + PAM THAL + IFNa + DEX THAL + pred THAL THAL THAL + pred PAD BORT BORT + THAL Placebo Placebo No maintenance PAM or no maintenance IFNa + DEX Pred IFNa No maintenance No maintenance VAD THAL THAL or IFNa Yes Yes (TTP and EFS) Yes Yes (EFS) Yes (EFS) Yes Yes (EFS) Yes Yes Yes Yes No Yes No No Yes Yes No No No No No Facon T. Hematology 2015;279-85
34 Conclusion.
35 Consolidation to maintenance therapy Goal to achieve deep response Maintained with less intense therapy
36 Recommendations for therapy after ASCT Consolidation after auto-hct is not routinely recommended but can be considered in the setting of a clinical trial. Maintenance with an immunomodulatory drug (thalidomide or lenalidomide) is recommended unless a contraindication exists (grade A). In most cases, lenalidomide is preferred because of improved survival data in the era of novel agents. In patients with high-risk disease with renal failure or adverse chromosome changes, post auto-hct bortezomib consolidation and maintenance may be considered (grade D). N. Shah et al. Biol Blood Marrow Transplant 21 (2015)
37 Current approaches to consolidation and maintenance for transplant eligible patients Mayo clinic use FISH-based risk stratification model termed msmart (Mayo Stratification of Myeloma and Risk-Adapted therapy) Intermediate risk [t(4;14) or 1q gain] VRd for 4 cycles followed by ASCT then bortezomibbased maintenance for 1 year High-risk patients [t(14;16), t(14;20), 17p deletion, or high-risk gene expression profile], bortezomib or carfilzomib-based maintenance following KRd (carfilzomib, lenalidomide, dexamethasone) induction for a minimum of 1 year after ASCT Standard-risk patients[trisomies, t(11;14), t(6;14)] 2 cycles of Rd consolidation followed by lenalidomide maintenance of limited duration (12 24 months) if VGPR has not been achieved following consolidation.
38 Current approaches to consolidation and maintenance for transplant eligible patients HOVON-65/GMMGHD4 trial, del(17p) treated with bortezomib induction and maintenance had a median PFS of 26.2 months versus 12 months in patients treated without bortezomib. VTd consolidation: PFS benefit; however, the high rates of peripheral neuropathy and treatment discontinuation remain a limitation. Retrospective study of 45 high-risk patients at Emory University, VRd was administered after ASCT on a 28-day cycle up to 3 years, then lenalidomide 10 mg/day single agent therapy thereafter. Median PFS was 32 months with a 3-year OS of 93 %, which significantly exceeds the median OS of 3 years in many studies of high-risk patients.
39 Minimal residual disease
40 The natural history of myeloma MGUS Smoldering Myeloma Early Myeloma Late Myeloma Plasma Cell Leukemia M-PROTEIN 100 Asymptomatic Symptomatic Active myeloma 2 ND RELAPSE 50 1 ST RELAPSE 20 Induction and ASCT 1 st line PLATEAU REMISSION Operational cure TIME
41 MRD modality and sensitivity of detection Bone Marrow Transplantation (2016) 51, 2 12
42 Flow cytometry testing for MRD in patients with treated MM Key characteristics distinguish malignant plasma cells from normal plasma cells: CD19 (all panels); expression of less CD38; a. CD45 b. CD56+ c. CD117+ d. CD27 e. CD81
43 Effect of sample size on flow cytometry testing for MRD in treated patients with MM All panels depict healthy (black) and malignant (green) plasma cells in a bone marrow sample obtained from the same patient. a. 84 malignant plasma cells were detected by analysing 3,000,000 events. b. 30 cells were detected in 1,000,000 events. c. 14 malignant cells were detected in 500,000 events. d. Only 6 malignant cells were detected in 100,000 events.
44 Allele-specific oligonucleotide-quantitative PCR (ASOqPCR) method to detect MRD J. Clin. Med. 2017, 6(10), 91
45 Next-generation sequencing method to detect minimal residual disease (MRD) J. Clin. Med. 2017, 6(10), 91
46 Prognostic value of MRD in post-asct BM samples for patients with MM according to MRD level as determined by deep sequencing (threshold: 10 6 ) PFS OS PFS Patients achieving conventional CR from ASCT PFS OS PFS Patients achieving conventional CR from BM MRD assessment Annals of Oncology 28: , 2017
47 Patients who did not receive post-asct treatment Correlation between NGS-based MRD assessment in autografts and clinical outcome Patients who receive post-asct treatment Annals of Oncology 28: , 2017
48 Influence of high-risk chromosomal abnormalities (HRCA) and MRD levels by NGS on prognosis of MM BM BM Autograft Autograft Annals of Oncology 28: , 2017
49 Comparison of MRD assays in multiple myeloma J. Clin. Med. 2017, 6(10), 9
50
How I Treat Transplant Eligible Myeloma Patients
How I Treat Transplant Eligible Myeloma Patients Michele Cavo Seràgnoli Institute of Hematology, Bologna University School of Medicine, Italy Podcetrtek, Slovene, April 14 th, 2012 NEW TREATMENT PARADIGM
More informationRole of consolidation therapy in Multiple Myeloma. Pieter Sonneveld. Erasmus MC Cancer Institute Rotterdam The Netherlands
Role of consolidation therapy in Multiple Myeloma Pieter Sonneveld Erasmus MC Cancer Institute Rotterdam The Netherlands Disclosures Research support : Amgen, Celgene, Janssen, Karyopharm Advisory Boards/Honoraria:
More informationVI. Autologous stem cell transplantation and maintenance therapy
Hematological Oncology Hematol Oncol 2013; 31 (Suppl. 1): 42 46 Published online in Wiley Online Library (wileyonlinelibrary.com).2066 Supplement Article VI. Autologous stem cell transplantation and maintenance
More informationInitial Therapy For Transplant-Eligible Patients With Multiple Myeloma. Michele Cavo, MD University of Bologna Bologna, Italy
Initial Therapy For Transplant-Eligible Patients With Multiple Myeloma Michele Cavo, MD University of Bologna Bologna, Italy Treatment Paradigm for Autotransplant-Eligible Patients With Multiple Myeloma
More informationConsolidation after Autologous Stem Cell Transplantion
Consolidation after Autologous Stem Cell Transplantion Joan Bladé Laura Rosiñol Department of Hematology Hospital Clínic de Barcelona Berlin, September 11 th 2011 Autologous Stem Cell Transplant in Younger
More informationTerapia del mieloma. La terapia di prima linea nel paziente giovane. Elena Zamagni
Terapia del mieloma La terapia di prima linea nel paziente giovane Elena Zamagni Istituto di Ematologia ed Oncologia Medica Seràgnoli Università degli Studi di Bologna Newly diagnosed MM Candidate for
More informationClinical Case Study Discussion: Maintenance in MM
www.comtecmed.com/comy comy@comtecmed.com Evangelos Terpos, MD, PhD National & Kapodistrian University of Athens, School of Medicine, Athens, Greece Clinical Case Study Discussion: Maintenance in MM Disclosure
More informationTo Maintain or Not to Maintain? Immunomodulators vs PIs Yes: Proteasome Inhibitors
To Maintain or Not to Maintain? Immunomodulators vs PIs Yes: Proteasome Inhibitors James Berenson, MD Institute for Myeloma and Bone Cancer Research West Hollywood, CA Financial Disclosures Takeda, Celgene
More informationInduction Therapy: Have a Plan. Sagar Lonial, MD Professor, Winship Cancer Institute Director of Translational Research, B-cell Malignancy Program
Induction Therapy: Have a Plan Sagar Lonial, MD Professor, Winship Cancer Institute Director of Translational Research, B-cell Malignancy Program Topics When to treat? Smoldering vs Symptomatic Risk stratification
More informationInduction Therapy in Transplant Eligible MM 2 December Tontanai Numbenjapon, M.D.
Induction Therapy in Transplant Eligible MM 2 December 2017 Tontanai Numbenjapon, M.D. What we need from induction therapy in NDMM Depth of response: MRD-negative, scr, CR Longest response Acceptable toxicity
More informationAutologous Stem Cell Transplanation as First line Treatment? (Against) Joan Bladé Berlin, September 9 th, 2011
Autologous Stem Cell Transplanation as First line Treatment? (Against) Joan Bladé Berlin, September 9 th, 2011 Significant impact of ASCT before the availability of novel agents? Randomized trials: Single
More informationMultiple myeloma, 25 (45) years of progress. The IFM experience in patients treated with frontline ASCT. Philippe Moreau, Nantes
Multiple myeloma, 25 (45) years of progress The IFM experience in patients treated with frontline ASCT Philippe Moreau, Nantes Shibata T. Prolonged survival in a case of multiple myeloma treated with high
More informationTo Maintain or Not to Maintain? Lymphoma and Myeloma 2015 Waldorf Astoria Hotel, New York
To Maintain or Not to Maintain? Lymphoma and Myeloma 2015 Waldorf Astoria Hotel, New York Sundar Jagannath Director, Multiple Myeloma Program Tisch Cancer Institute Mount Sinai Medical Center Maintenance
More informationApproach to the Treatment of Newly Diagnosed Multiple Myeloma. S. Vincent Rajkumar Professor of Medicine Mayo Clinic
Approach to the Treatment of Newly Diagnosed Multiple Myeloma S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of
More informationConsolidation and Maintenance therapy
University of Salamanca Consolidation and Maintenance therapy María-Victoria Mateos, MD, PhD University Hospital of Salamanca, Spain Disclosure form MVM has served as member of advisory boards or received
More informationNew Treatment Paradigms in Transplant-Eligible Myeloma Patients
New Treatment Paradigms in Transplant-Eligible Myeloma Patients Michele Cavo Seràgnoli Institute of Hematology, Bologna University School of Medicine, Italy Turkey, March 1 st 2013 NEW TREATMENT PARADıGM
More informationAutologous Stem Cell Transplantation in Multiple Myeloma Optimal Frontline Therapy and Maintenance Therapy
Autologous Stem Cell Transplantation in Multiple Myeloma Optimal Frontline Therapy and Maintenance Therapy Donna E. Reece, M.D. Princess Margaret Hospital Toronto, ON CANADA 10 December 2011 ASCT in Myeloma..
More informationNovel Combination Therapies for Untreated Multiple Myeloma
Novel Combination Therapies for Untreated Multiple Myeloma Andrzej J. Jakubowiak, MD, PhD Director, Myeloma Program New York, NY, October 27, 201 Disclosures 2 Employee Consultant Major Stockholder Speakers
More informationTiming of Transplant for Multiple Myeloma
Timing of Transplant for Multiple Myeloma Wenming CHEN Beijing Chaoyang Hospital Capital Medical University Multiple myeloma resrarch center of Beijing Initial Approach to Treatment of Myeloma Nontransplantation
More informationUpdate on Multiple Myeloma Treatment
Update on Multiple Myeloma Treatment Professor Chng Wee Joo Director National University Cancer Institute of Singapore (NCIS) National University Health System (NUHS) Deputy Director Cancer Science Institute,
More informationIs autologous stem cell transplant the best consolidation after initial therapy?
Is autologous stem cell transplant the best consolidation after initial therapy? William Bensinger, MD Professor of Medicine, Division of Oncology University of Washington School of Medicine Director,
More informationPost Transplant Maintenance- for everyone? Disclosures
Post Transplant Maintenance- for everyone? NO Because of limited survival data, not all patients require maintenance April 2012 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Joseph Mikhael,
More informationChristine Chen Princess Margaret Cancer Centre September 2013
Christine Chen Princess Margaret Cancer Centre September 2013 Disclosures Research Support Celgene, Janssen, GSK Employee N/A Consultant N/A Major Stockholder Speakers Bureau/ Scientific Advisory Board
More informationRole of Maintenance and Consolidation Therapy in Multiple Myeloma: A Patient-centered Approach
Role of Maintenance and Consolidation Therapy in Multiple Myeloma: A Patient-centered Approach Jacob Laubach, MD Assistant Professor in Medicine Harvard Medical School Clinical Director of the Jerome Lipper
More informationMaintenance therapy after autologous transplantation
Maintenance therapy after autologous transplantation Sonja Zweegman MD PhD Department of Hematology Amsterdam The Netherlands Disclosures Research funding from Celgene, Takeda and Janssen Participation
More informationContinuous Therapy as a Standard of Care CON. JL Harousseau Institut de Cancérologie de l Ouest Nantes Saint Herblain France
Continuous Therapy as a Standard of Care CON JL Harousseau Institut de Cancérologie de l Ouest Nantes Saint Herblain France 1 In France and in the IFM all debates 2 In France and in the IFM all debates
More informationCOMy Congress The case for IMids. Xavier Leleu. Hôpital la Milétrie, PRC, CHU, Poitiers, France
Xavier Leleu Hôpital la Milétrie, PRC, CHU, Poitiers, France The case for IMids COMy Congress 21 Disclosures Grants/research support: Amgen, Bristol-Myers Squibb, Celgene, Janssen, Millennium/Takeda, Novartis,
More informationNew IMWG Response Criteria
New IMWG Response Criteria Shaji Kumar, M.D. Professor of Medicine Division of Hematology Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of Medicine Mayo
More informationDisclosures for Palumbo Antonio, MD
Disclosures for Palumbo Antonio, MD Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Honoraria Scientific Advisory Board o relevant conflicts of interest to declare o relevant
More informationUK MRA Myeloma XII Relapsed Intensive Study CI: Prof Gordon Cook
UK Myeloma Research Alliance Myeloma XII study (ACCoRD): Augmented Conditioning & Consolidation in Relapsed Disease UK MRA Myeloma XII Relapsed Intensive Study CI: Prof Gordon Cook Sponsor ID: Pending
More informationRole of Stem Cell Transplantation in Multiple Myeloma: The Changing Landscape
Role of Stem Cell Transplantation in Multiple Myeloma: The Changing Landscape Simrit Parmar, MD MDACC Houston, TX, USA Why Transplant in the Era of Novel Therapy? Safe (TRM
More informationDebate: Is transplant a necessity or a choice? Focus on the necessity for CR and MRD. Answer: NO
Debate: Is transplant a necessity or a choice? Focus on the necessity for CR and MRD. Answer: NO Tomer M. Mark Department of Medicine, Division of Hematology / Oncology Weill-Cornell Medical College /
More informationCuring Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham
Curing Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham What is cure after all? Getting rid of it? Stopping treatment without
More informationMYELOMA MAINTENANCE BEST PRACTICES:
MYELOMA MAINTENANCE BEST PRACTICES: POST THERAPY & POST TRANSPLANT Aric Hall, MD Assistant Professor University of Wisconsin Hospital and Clinics INTRODUCTION MYELOMA Clonal plasma cell malignancy leading
More informationUnmet Medical Needs and Latest Multiple Myeloma Treatment
Unmet Medical Needs and Latest Multiple Myeloma Treatment Professor Chng Wee Joo Director National University Cancer Institute of Singapore (NCIS) National University Health System (NUHS) Deputy Director
More informationMyeloma Support Group: Now and the Horizon. Brian McClune, DO
Myeloma Support Group: Now and the Horizon Brian McClune, DO Disclosures Consultant to Celgene Objectives Transplant for myeloma- is there any thing new? High risk disease University protocols New therapies?
More informationProgress in Multiple Myeloma
Progress in Multiple Myeloma Sundar Jagannath, MD Professor, New York Medical College Adjunct Professor, New York University St. Vincent s Comprehensive Cancer Center, NY Faculty Disclosure Advisory Board:
More informationMultiple Myeloma Updates 2007
Multiple Myeloma Updates 2007 Brian Berryman, M.D. Multiple Myeloma Updates 2007 Goals for today: Understand the staging systems for myeloma Understand prognostic factors in myeloma Review updates from
More informationManagement of Multiple Myeloma: The Changing Paradigm
Management of Multiple Myeloma: The Changing Paradigm High-Dose Chemotherapy and Stem Cell Transplantation Todd Zimmerman, MD University of Chicago Medical Center Case Presentation R.M. is a 64 year old
More informationChoosing upfront and salvage therapy for myeloma in the ASEAN context
Choosing upfront and salvage therapy for myeloma in the ASEAN context Daryl Tan Consultant Department of Haematology Singapore General Hospital Adjunct Assistant Professor Duke-NUS Graduate Medical School
More informationUpfront Therapy for Myeloma Tailoring Therapy across the Disease Spectrum
Upfront Therapy for Myeloma Tailoring Therapy across the Disease Spectrum S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic
More informationStandard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant
Standard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant Pr Philippe Moreau University Hospital, Nantes, France MP: Standard of care until 2007 J Clin Oncol
More informationManaging Newly Diagnosed Multiple Myeloma
Managing Newly Diagnosed Multiple Myeloma 26 Jan 2018 Alfred Garfall, MD Assistant Professor of Medicine Diagnosis of Multiple Myeloma Traditional criteria: Monoclonal plasma cells + attributable CRAB
More informationTreatment of elderly multiple myeloma patients
SAMO Interdisciplinary Workshop on Myeloma March 30 th -31 st 2012, Seehotel Hermitage, Lucerne Treatment of elderly multiple myeloma patients Federica Cavallo, MD, PhD Federica Cavallo, MD, PhD Division
More informationCOMy Congress A New Era of Advances in Myeloma. S. Vincent Rajkumar Professor of Medicine Mayo Clinic
A New Era of Advances in Myeloma S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of Medicine Mayo Clinic Comprehensive
More informationMAINTENANCE AND CONTINUOUS THERAPY OF MYELOMA. Myeloma Day 11/18/2017 Aric Hall, MD Assistant Professor UW School of Medicine & Public Health
MAINTENANCE AND CONTINUOUS THERAPY OF MYELOMA Myeloma Day 11/18/2017 Aric Hall, MD Assistant Professor UW School of Medicine & Public Health Disclosures I have no significant conflicts of interest to disclose.
More informationMultiple myeloma. November 24, 2017 at Vientiane, Laos
Multiple myeloma November 24, 2017 at Vientiane, Laos Teeraya Puavilai, M.D. Division of Hematology, Department of Medicine Faculty of Medicine Ramathibodi, Mahidol University, Thailand Multiple myeloma
More informationIs Transplant a Necessity or a Choice: Focus on the necessity for CR and MRD
Is Transplant a Necessity or a Choice: Focus on the necessity for CR and MRD Ajai Chari, MD Associate Professor of Medicine Director of Clinical Research Multiple Myeloma Program Mount Sinai Medical Center
More informationCME Information LEARNING OBJECTIVES
CME Information LEARNING OBJECTIVES Identify patients with MM who have undergone autologous stem cell transplant and would benefit from maintenance lenalidomide. Counsel older patients (age 65 or older)
More informationOptimal maintenance and consolidation therapy for multiple myeloma in actual clinical practice
REVIEW Korean J Intern Med 2016;31:809-819 Optimal maintenance and consolidation therapy for multiple myeloma in actual clinical practice Ho Sup Lee 1 and Chang-Ki Min 2 1 Department of Internal Medicine,
More informationSmoldering Myeloma: Leave them alone!
Smoldering Myeloma: Leave them alone! David H. Vesole, MD, PhD Co-Director, Myeloma Division Director, Myeloma Research John Theurer Cancer Center Hackensack University Medical Center Prevalence 1960 2002
More informationIl trattamento del Mieloma su stratificazione di rischio: è oggi possibile?
Il trattamento del Mieloma su stratificazione di rischio: è oggi possibile? Francesca Gay, MD Divisione Ematologia 1 AO Città della Salute e della Scienza, Torino, Italy Focus sul MM 2014 Cagliari, 30-31
More informationIs Myeloma Curable in 2012?
Is Myeloma Curable in 2012? YES Cure is living long enough to die of another cause April 2012 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Joseph Mikhael, MD, MEd, FRCPC Staff Hematologist,
More informationLONDON CANCER NEWS DRUGS GROUP RAPID REVIEW
LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW Bortezomib as first line induction prior to melphalan and autologous stem cell transplantation (ASCT) in untreated symptomatic multiple myeloma patients suitable
More informationCREDIT DESIGNATION STATEMENT
CME Information LEARNING OBJECTIVES Integrate emerging research information on the use of proteasome inhibitors and immunomodulatory agents to individualize induction treatment recommendations and maintenance
More informationStudy Objectives: GMMG MM5
Study Objectives: GMMG MM5 1.) Demonstration of non-inferiority of VCD induction therapy compared to PAd induction therapy with respect to response rate (very good partial remission or better; response
More informationManagement of Multiple Myeloma
Management of Multiple Myeloma Damian J. Green, MD Fred Hutchinson Cancer Research Center/ Seattle Cancer Care Alliance New Treatment Options Have Improved OS in MM Kumar SK, et al. Blood. 2008;111:2516-2520.
More informationModule 3: Multiple Myeloma Induction and Transplant Strategies Treatment Planning
Module 3: Multiple Myeloma Induction and Transplant Strategies Treatment Planning Challenge Question: Role of Autologous Stem Cell Transplant Which of the following is true about eligibility for high-dose
More informationStem Cell Transplant for Myeloma: The New Landscape
Stem Cell Transplant for Myeloma: The New Landscape Sergio A. Giralt, MD Chief, Adult Bone Marrow Transplant Service Division of Hematologic Oncology Department of Medicine Memorial Sloan-Kettering Cancer
More informationClinical Decision Making in Multiple Myeloma for the Transplant-Eligible Patient Upfront Transplant Versus Maintenance Therapy
Clinical Decision Making in Multiple Myeloma for the Transplant-Eligible Patient Upfront Transplant Versus Maintenance Therapy Noa Biran, MD, and David Vesole, MD, PhD Introduction High dose chemotherapy
More informationHighlights from EHA Mieloma Multiplo
Highlights from EHA Mieloma Multiplo Michele Cavo Istituto di Ematologia L. e A. Seràgnoli Alma Mater Studiorum Università degli studi di Bologna Firenze, 22-23 Settembre 27 Myeloma XI TE pathway 7 R :
More informationTREATMENT FOR NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA
TREATMENT FOR NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA Ekarat Rattarittamrong, MD Division of Hematology Department of Internal Medicine Faculty of Medicine Chiang Mai University OUTLINE Overview of treatment
More informationMichel Delforge Belgium. New treatment options for multiple myeloma
Michel Delforge Belgium New treatment options for multiple myeloma Progress in the treatment of MM over the past 40 years 1962 Prednisone + melphalan 1990s Supportive care 1999 First report on thalidomide
More informationPosttransplantation Maintenance Therapy and Optimal Frontline Therapy in Myeloma
CONTROVERSIES AND UPDATES IN MULTIPLE MYELOMA Posttransplantation Maintenance Therapy and Optimal Frontline Therapy in Myeloma Donna E. Reece 1 1 Princess Margaret Hospital, Toronto, ON One of the major
More informationGetting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions
Getting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions Friday, December 8, 2017 Atlanta, Georgia Friday Satellite Symposium preceding the 59th ASH Annual Meeting &
More informationIMiDs (Immunomodulatory drugs) and Multiple Myeloma
www.comtecmed.com/comy comy@comtecmed.com IMiDs (Immunomodulatory drugs) and Multiple Myeloma Xavier Leleu Service des Maladies du Sang Hôpital Huriez, CHRU, Lille, France www.comtecmed.com/comy comy@comtecmed.com
More informationShould we treat Smoldering MM patients? María-Victoria Mateos University Hospital of Salamanca Salamanca. Spain
Should we treat Smoldering MM patients? María-Victoria Mateos University Hospital of Salamanca Salamanca. Spain Should we treat some patients with Stage I MM? Len-dex is a promising and atractive option
More informationMultiple Myeloma: ASH 2008
Multiple Myeloma: ASH 2008 Steven Coutre, M.D. Associate Professor of Medicine Division of Hematology Stanford University School of Medicine About These Slides These slides accompany CCO s comprehensive
More informationManagement of Multiple
Management of Multiple Myeloma in the Elderly Xavier Leleu Service des Maladies du Sang Hôpital Huriez, CHRU, Lille, France INSERM U837, équipe 3 IRCL, CHRU, Lille, France IMPRT Institut de Médecine Prédictive
More informationMeu paciente realizou um TACTH na 1a linha, e agora? Tandem, Manutenção, Consolidação? Marcelo C Pasquini, MD, MS Medical College of Wisconsin
Meu paciente realizou um TACTH na 1a linha, e agora? Tandem, Manutenção, Consolidação? Marcelo C Pasquini, MD, MS Medical College of Wisconsin Post Auto HCT Options for MM Maintenance Lenalidomide vs.
More informationWhat New in Hematopoietic Stem Cell Transplantation? Joseph M. Tuscano, M.D. UCD Cancer Center
What New in Hematopoietic Stem Cell Transplantation? Joseph M. Tuscano, M.D. UCD Cancer Center 1 JOSEPH TUSCNO, MD WHAT S NEW IN HEMATOPOEITIC STEM CELL TRANSPLANTATION? RELEVANT FINANCIAL RELATIONSHIPS
More informationTreatment Advances in Multiple Myeloma: Expert Perspectives on Translating Clinical Data to Practice
Treatment Advances in Multiple Myeloma: Expert Perspectives on Translating Clinical Data to Practice Friday, December 2, 2016 San Diego, California This program is supported by educational grants from
More informationMULTIPLE MYELOMA. TREATMENT in 2017 MC. VEKEMANS
MULTIPLE MYELOMA TREATMENT in 2017 MC. VEKEMANS NATURAL HISTORY of MM WHO SHOULD BE TREATED? DEFINITION MGUS Smouldering Multiple Myeloma Symptomatic Multiple Myeloma Monoclonal component (blood and/or
More informationInternational Myeloma Foundation Patient and Family Seminar
International Myeloma Foundation Patient and Family Seminar Vienna, Austria May 6 th, 2006 New Development in Diagnosis & Treatments Brian G.M. Durie, M.D., Chairman International Myeloma Foundation What
More informationMinimal residual disease. Bruno Paiva University of Navarra, Spain
Minimal residual disease Bruno Paiva University of Navarra, Spain 1st World Congress on Controversies in Multiple Myeloma. Bangkok, Thailand. May 11-13 214 Oprozomib (ONX 912) Phase I/II Autologous bone
More informationMultiple Myeloma Brian Berryman, M.D. March 8 th, 2014
Multiple Myeloma 2014 Brian Berryman, M.D. March 8 th, 2014 Kyle, R. A. et al. Blood 2008;111:2962-2972 Updates in Multiple Myeloma CCO Independent Conference Coverage of the 2013 Annual Meeting of
More informationInduction Therapy & Stem Cell Transplantation for Myeloma
Induction Therapy & Stem Cell Transplantation for Myeloma William Bensinger, MD Professor of Medicine, Division of Oncology University of Washington School of Medicine Director, Autologous Stem Cell Transplant
More informationMultiple Myeloma: Diagnosis and Primary Treatment
Multiple Myeloma: Diagnosis and Primary Treatment George Somlo, MD City of Hope Comprehensive Cancer Center NCCN.org For Clinicians NCCN.org/patients For Patients Educational Objectives Discuss considerations
More informationRisk stratification in the older patient; what are our priorities?
Risk stratification in the older patient; what are our priorities? Sonja Zweegman MD PhD Amsterdam The Netherlands Negative impact of age on survival Meta-analysis of European trials (MP vs MPT, VMP vs
More informationmsmart Mayo Stratification for Myeloma And Risk-adapted Therapy Newly Diagnosed Myeloma
msmart Mayo Stratification for Myeloma And Risk-adapted Therapy Newly Diagnosed Myeloma msmart Multiple myeloma is increasingly recognized as more than one disease, characterized by marked cytogenetic,
More informationNovel treatment strategies for multiple myeloma: a focus on oral proteasome inhibitors
Novel treatment strategies for multiple myeloma: a focus on oral proteasome inhibitors Antonio Palumbo M.D. Takeda Pharmaceuticals International AG Introduction Multiple genetically-distinct subclones
More informationCurrent Management of Multiple Myeloma. December 2012 Kevin Song MD FRCPC Leukemia/BMT Program of B.C.
Current Management of Multiple Myeloma December 2012 Kevin Song MD FRCPC Leukemia/BMT Program of B.C. Disclosures Honoraria Speaker Celgene, Janssen, Novartis Celgene, Janssen Research Support Celgene
More informationHow to treat a newly diagnosed young patient with multiple myeloma
How to treat a newly diagnosed young patient with multiple myeloma J.F. San Miguel University of Salamanca, Spain Department of Haematology University of Salamanca Cancer Research Centre Disclosures for
More informationKalyan Nadiminti, MBBS 4/13/18
A Single Autologous Stem Cell Transplant (ASCT) followed by two years of post-transplant therapy is safe in Older Recently Diagnosed Multiple Myeloma (MM) Patients. Preliminary Results from the Prospective
More informationTreatment of elderly patients with multiple myeloma
Treatment of elderly patients with multiple myeloma Mario Boccadoro DIVISIONE UNIVERSITARIA DI EMATOLOGIA AZIENDA OSPEDALIERA SAN GIOVANNI TORINO, ITALY Improved survival in multiple myeloma and the impact
More informationTransplant in MM patients: Early versus late. Mario Boccadoro. Barcelona
Transplant in MM patients: Early versus late Barcelona 8-9-2012 Mario Boccadoro DIVISIONE UNIVERSITARIA DI EMATOLOGIA AZIENDA OSPEDALIERA SAN GIOVANNI TORINO, ITALY Transplant in MM patients: Early versus
More informationNovel Therapies for the Treatment of Newly Diagnosed Multiple Myeloma
Novel Therapies for the Treatment of Newly Diagnosed Shaji K. Kumar, MD Professor of Medicine Mayo Clinic College of Medicine Consultant, Division of Hematology Medical Director, Cancer Clinical Research
More informationDaratumumab: Mechanism of Action
Phase 3 Randomized Controlled Study of Daratumumab, Bortezomib and Dexamethasone (D) vs Bortezomib and Dexamethasone () in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): CASTOR* Antonio
More informationBest of ASH 2017 DR. BRIAN DURIE. Brian GM Durie, MD Thursday, January 11, 2018
Best of ASH 2017 DR. BRIAN DURIE Brian GM Durie, MD Thursday, January 11, 2018 1 ASH Overview 2017 Total myeloma abstracts: 981 Important/Interesting: oral ~40 posters ~60 100 2 Which abstracts impact
More informationExperience with bortezomib (Velcade) in multiple myeloma. Peter Černelč Clinical center Ljubljana Department of Haematology
Experience with bortezomib (Velcade) in multiple myeloma Peter Černelč Clinical center Ljubljana Department of Haematology Our experience with bortezomib (Velcade) in multiple myeloma 1. Our first experience
More informationTreatment Strategies for Transplant-ineligible NDMM Patients
1 Treatment Strategies for Transplant-ineligible NDMM Patients Thierry Facon, MD Professor of Hematology Service des Maladies du Sang University of Lille Lille, France Multiple Myeloma affects primarily
More informationMULTIPLE MYELOMA. The clonoseq Assay can predict progressionfree survival in myeloma patients
MULTIPLE MYELOMA With current therapies, complete response (CR) is reached in 3-5% of multiple myeloma () patients. 1 However, most of these patients will experience relapse due to the persistence of residual
More informationPomalidomide (CC4047) Plus Low-Dose Dexamethasone as Therapy for Relapsed Multiple Myeloma. Lacy MQ et al. J Clin Oncol 2009;27(30):
Pomalidomide (CC4047) Plus Low-Dose Dexamethasone as Therapy for Relapsed Multiple Myeloma Lacy MQ et al. J Clin Oncol 2009;27(30):5008-14. Introduction A curative therapy for multiple myeloma (MM) does
More informationTherapeutic effects of autologous hematopoietic stem cell transplantation in multiple myeloma patients
EXPERIMENTAL AND THERAPEUTIC MEDICINE 6: 977-982, 2013 Therapeutic effects of autologous hematopoietic stem cell transplantation in multiple myeloma patients CHENGCHENG FU, JUAN WANG, XUE XIN, HUI LIU,
More informationMULTIPLE MYELOMA. The clonoseq Assay can predict progressionfree survival in myeloma patients
MULTIPLE MYELOMA With current therapies, complete response (CR) is reached in 3-5% of multiple myeloma () patients. 1 However, most of these patients will experience relapse due to the persistence of residual
More informationStem cell transplantation in elderly, but fit multiple myeloma patients
Stem cell transplantation in elderly, but fit multiple myeloma patients Mohamad MOHTY, MD, PhD Clinical Hematology and Cellular Therapy Dpt. Université Pierre & Marie Curie, Hôpital Saint-Antoine INSERM
More informationManaging Myeloma Virtual Grand Rounds Newly Diagnosed, Transplant Eligible Patient. Case Study
Managing Myeloma Virtual Grand Rounds Newly Diagnosed, Transplant Eligible Patient Case Study 2 2011 Newly Diagnosed Patient The patient is a 61-year-old Caucasian female History of high blood pressure
More informationMultiple Myeloma in 2016 Progress and Challenges DONNA E. REECE, M.D. PRINCESS MARGARET CANCER CENTRE 01 APRIL 2016
Multiple Myeloma in 2016 Progress and Challenges DONNA E. REECE, M.D. PRINCESS MARGARET CANCER CENTRE 01 APRIL 2016 Key Features of Myeloma Biology Myeloma is not one disease 1 At least 7 subtypes based
More informationAntibodies are a standard part of first relapse management in multiple myeloma (MM): Yes
Antibodies are a standard part of first relapse management in multiple myeloma (MM): Yes Ajay Nooka, MD MPH FACP Assistant Professor, Division of Bone Marrow Transplant Winship Cancer Institute, Emory
More informationCurrent management of multiple myeloma. Jorge J. Castillo, MD Assistant Professor of Medicine Harvard Medical School
Current management of multiple myeloma Jorge J. Castillo, MD Assistant Professor of Medicine Harvard Medical School JorgeJ_Castillo@dfci.harvard.edu Multiple myeloma MM is a plasma cell neoplasm characterized
More information